Peter Singer has argued that we should not proceed with a hypothetical life-extension drug, based on a scenario in which developing the drug would fail to achieve the greatest sum of happiness over time. However, this is the wrong test. If we ask, more simply, which policy would be more benevolent, we reach a different conclusion from Singer’s: even given his (admittedly questionable) scenario, development of the drug should go ahead. Singer’s rigorous utilitarian position pushes him in the direction of an implausible “total view” utilitarianism when it encounters the problems presented by certain thought experiments. A more pluralistic account of the nature of morality promises to solve these problems, and in this case it reaches a benevolent recommendation on life-extension technology.
Statistics from Altmetric.com
Competing interests None.
Provenance and Peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.